Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immunome Inc.IMNM · Entity 4219 | CHIEF BUSINESS OFFICER | August 04, 2026 | August 06, 2026 |
| Olema Pharmaceuticals, Inc.OLMA · Entity 613 | Chief Business Officer | February 01, 2023 | February 02, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immunome Inc.
Report date August 04, 2026 · Filed August 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-08-04 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-08-04 · Exercise / conversion · Acquired 50,366 · Balance 50,366 Row 2 · 2026-08-04 · Exercise / conversion · Acquired 40,250 · Balance 90,616 Row 3 · 2026-08-04 · Sale · Disposed 90,616 · Balance 0 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026. F2: The weighted average sale price for the transaction report was $25.09, and the range of prices were between $25.00 and $25.295, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.92 · Expires 2034-08-08 | Direct | 78,542 |
Reported balance
After 2026-08-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-04 · Exercise / conversion · Disposed 50,366 · Balance 78,542 F3: 25% of the shares subject to the option vested on August 9, 2025, and the remaining shares will vest monthly thereafter over three years. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.60 · Expires 2035-07-28 | Direct | 120,750 |
Reported balance
After 2026-08-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-08-04 · Exercise / conversion · Disposed 40,250 · Balance 120,750 F4: 25% of the shares subject to the options vested on July 29, 2026, and the remaining shares will vest monthly thereafter over three years. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026.
F2: The weighted average sale price for the transaction report was $25.09, and the range of prices were between $25.00 and $25.295, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F3: 25% of the shares subject to the option vested on August 9, 2025, and the remaining shares will vest monthly thereafter over three years.
F4: 25% of the shares subject to the options vested on July 29, 2026, and the remaining shares will vest monthly thereafter over three years.
Olema Pharmaceuticals, Inc.
Report date February 01, 2023 · Filed February 02, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.87 · Expires 2033-01-31 | Direct | 150,000 |
Reported balance
After 2023-02-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-01 · Grant · Acquired 150,000 · Balance 150,000 F1: 25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2021 Filed Jun 11, 2021 20:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 300 | $28.30 | $8,490.00 |
DisclosureSEC source: 0001415889-21-002957 · form4-06112021_010653.xml · nonDerivative · entry 2 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,741 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · price: The weighted average sale price for the transaction reported was $28.30, and the range of prices were between $27.79 and $28.63. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 20:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionCommon Stock | 5,251 | $2.06 | $10,838.06 |
DisclosureSEC source: 0001415889-21-002957 · form4-06112021_010653.xml · nonDerivative · entry 1 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2021 Filed May 20, 2021 00:18 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionStock Option (Right to Buy) · Derivative | 57,763 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001415889-21-002578 · form4-05192021_050534.xml · derivative · entry 4 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,297 Underlying: Common Stock · 57,763 shares Expires 2030-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to the option vest in a series of 48 successive equal monthly installments measured from June 10, 2020, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| May 18, 2021 Filed May 20, 2021 00:18 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 8,621 | $24.81 | $213,887.01 |
DisclosureSEC source: 0001415889-21-002578 · form4-05192021_050534.xml · nonDerivative · entry 3 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,790 F2 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F4 · price: The weighted average sale price for the transaction reported was $24.81, and the range of prices were between $24.52 and $25.23. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| May 18, 2021 Filed May 20, 2021 00:18 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 49,142 | $24.03 | $1,180,882.26 |
DisclosureSEC source: 0001415889-21-002578 · form4-05192021_050534.xml · nonDerivative · entry 2 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,411 F2 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F3 · price: The weighted average sale price for the transaction reported was $24.03, and the range of prices were between $23.51 and $24.50. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| May 18, 2021 Filed May 20, 2021 00:18 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionCommon Stock | 57,763 | $2.06 | $119,222.83 |
DisclosureSEC source: 0001415889-21-002578 · form4-05192021_050534.xml · nonDerivative · entry 1 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,553 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,790 shares acquired under the issuer's Employee Stock Purchase Plan on May 14, 2021. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 23:07 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $45.63 | $0.00 |
DisclosureSEC source: 0001209191-21-021112 · doc4.xml · derivative · entry 1 Horn Kinney · CIK 0001831215 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-03-14 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on March 15, 2022 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| November 18, 2020 Filed Nov 19, 2020 23:44 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 89,670 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0001209191-20-059513 · doc4.xml · derivative · entry 2 Horn Kinney · CIK 0001831215 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,670 Underlying: Common Stock · 89,670 shares Expires 2030-11-17 F2 · derivative.exercise_date: 25% of the shares subject to the option vest on November 18, 2021 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| June 10, 2020 Filed Nov 19, 2020 23:44 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 252,060 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001209191-20-059513 · doc4.xml · derivative · entry 1 Horn Kinney · CIK 0001831215 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,060 Underlying: Common Stock · 252,060 shares Expires 2030-06-09 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 48 successive equal monthly installments measured from June 10, 2020, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.